Todd A. Alonzo, PhD

Professor of Research Population and Public Health Sciences

Group Statistician for Children's Oncology Group

Image of Todd A. Alonzo, PhD
Is this your profile? Click to edit

Overview

Todd Alonzo is a Professor of Research in the Department of Preventive Medicine, University of Southern California. He received his undergraduate degree at the California State Polytechnic University, San Luis Obispo, California in Statistics in 1994 and received both his MS and his PhD in Biostatistics in 1997 and 2000 from the University of Washington, Seattle. Dr. Alonzo’s main areas of research interest are the statistical methods for analysis of biomarkers and medical diagnostic and screening tests, clinical trials, and the design and analysis of pediatric acute myelogenous leukemia studies. He has published over 290 peer-reviewed articles.

Dr. Alonzo has been member of the Editorial Board for Biometrics, Pediatric Blood Cancer, and Biometrical Journal and has acted as a reviewer for 30 scientific journals. He is a member of several Data Safety and Monitoring Boards. Dr. Alonzo was the President of the International Biometric Society Western Northern America Region (WNAR) in 2009. He is a Fellow of the American Statistical Association.

Awards

  • Fellow, American Statistical Association, 2018
  • The International Society for Magnetic Resonance in Medicine: Outstanding Teacher Award, 2017
  • University of Washington: Senior Biostatistics Award, Department of Biostatistics, 2000
  • ENAR Biometrics Society Distinguished Student Paper Award, 1999
  • WNAR Biometrics Society Best Student Oral Presentation, 1999
  • NIH: Predoctoral Cardiovascular Biostatistics Training Grant, 1995

Research Funding

  • Children's Oncology Group Statistics and Data Center
    NIH · U10CA180899 · Apr 15, 2014 – Feb 29, 2032 · Role: Principal Investigator
  • Bias correction optimizes the choice of screening test for early cancer detection
    NIH · R03CA136048 · Sep 1, 2009 – Aug 31, 2012 · Role: Principal Investigator

Publications

  • Sociodemographic Factors Associated With Later Stage at Diagnosis of Pediatric Germ Cell Tumors: A Report From Children’s Oncology Group Registries ACCRN07 and APEC14B1. Pediatr Blood Cancer. 2026 Aug 04.. View in PubMed
  • AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children’s Oncology Group. J Clin Oncol. 2026 Jul 24.. View in PubMed
  • Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity. Blood Adv. 2026 Jul 14; 10(13):4814-4827.. View in PubMed
  • Combining menin and MEK inhibition to target poor prognosis KMT2A-rearranged RAS pathway-mutant acute myeloid leukemia. Blood Adv. 2026 Jul 14; 10(13):4757-4771.. View in PubMed
  • Childhood Cancer Data Initiative Participant Index: Mapping Pediatric Cancer Data to Facilitate Cross-Study Integrated Analysis. JCO Clin Cancer Inform. 2026 Apr; 10(2):e2500387.. View in PubMed
  • HLA-DR expression at diagnosis is not predictive of relapse risk post allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a report from the Children’s Oncology Group. Haematologica. 2026 Mar 26.. View in PubMed
  • Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease. Blood Adv. 2026 Mar 10; 10(5):1576-1586.. View in PubMed
  • Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults. J Natl Cancer Inst. 2026 Feb 01; 118(2):199-204.. View in PubMed
  • Germline Cancer Predisposition Results From the National Cancer Institute-Children’s Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2025 Oct; 9:e2500742.. View in PubMed
  • EZH2-driven immune evasion at disease presentation defines a targetable high-risk subset of acute leukemia exemplified by t(16;21) FUS::ERG AML. bioRxiv. 2025 Sep 18.. View in PubMed